PULMATRIX, INC. Retained Earnings
PULMATRIX, INC. (PULM) had Retained Earnings of -$304.53 million as of 2026-06-30, per its S-4/A filed 2026-09-17.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-09-17
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$304.53M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$303.49M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$302.32M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$301.39M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$304.53M S-4/A · filed 2026-09-17 | |
| 2026-03-31 | -$303.49M S-4/A · filed 2026-08-03 | |
| 2025-12-31 | -$302.32M S-4/A · filed 2026-09-17 | |
| 2025-09-30 | -$301.39M 10-Q · filed 2025-10-16 | |
| 2025-06-30 | -$300.51M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | -$298.96M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | -$297.16M S-4/A · filed 2026-09-17 | |
| 2024-09-30 | -$295.17M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | -$292.58M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$286.77M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | -$287.60M 10-K · filed 2025-03-21 | |
| 2023-09-30 | -$285.51M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$281.74M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | -$277.92M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | -$273.48M 10-K · filed 2024-03-28 | |
| 2022-09-30 | -$269.26M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$264.21M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | -$259.61M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$254.64M 10-K · filed 2023-03-30 | |
| 2021-09-30 | -$250.61M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | -$242.43M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | -$238.57M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | -$234.47M 10-K · filed 2022-03-29 | |
| 2020-09-30 | -$231.57M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | -$221.02M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | -$219.85M 10-Q · filed 2020-05-14 | |
| 2019-12-31 | -$215.16M 10-K · filed 2021-03-23 | |
| 2019-09-30 | -$211.12M 10-Q · filed 2019-11-01 | |
| 2019-06-30 | -$207.56M 10-Q · filed 2019-08-05 | |
| 2019-03-31 | -$199.72M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | -$194.56M 10-K · filed 2020-03-26 | |
| 2018-09-30 | -$190.23M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | -$185.41M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | -$179.22M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | -$174.00M 10-K · filed 2019-02-19 | |
| 2017-09-30 | -$169.48M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | -$165.03M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | -$159.43M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | -$155.95M 10-K · filed 2018-03-13 | |
| 2016-09-30 | -$146.12M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | -$142.96M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | -$133.77M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | -$128.10M 10-K · filed 2017-03-10 | |
| 2015-09-30 | -$123.57M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | -$118.64M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | -$10.36M 10-K · filed 2015-06-10 | |
| 2014-12-31 | -$101.94M 10-K · filed 2016-03-10 | -$8.81M 10-Q · filed 2015-02-13 |
| 2014-09-30 | -$7.09M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | -$5.38M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | -$3.67M 10-K · filed 2015-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |